MNKD | MannKind Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	6.38 - 6.57
52 Week Range	3.17 - 7.63
Beta	1.22
Implied Volatility	56.59%
IV Rank	20.91%
Day's Volume	1,560,612
Average Volume	2,716,898
Shares Outstanding	275,778,000
Market Cap	1,759,463,640
Sector	Healthcare
Industry	Biotechnology
IPO Date	2004-07-28

Valuation
Profitability
Growth
Health
P/E Ratio	79.75
Forward P/E Ratio	N/A
EPS	0.08
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	411
Country	USA
Website	MNKD

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.

MNKD's peers: BMRN, PCVX, LQDA, LEGN, TECH, UTHR, LRMR, DAWN, KNSA, VSTM, IMGN, IMMP, ICPT, ELEV, RLFFD, ACER, NRXPW, KTTA, SABS, INKT, AFMD, ADAP, SGMO

*Chart delayed

Analyzing fundamentals for MNKD we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is good and Health is very weak. For more detailed analysis please see MNKD Fundamentals page.

Watching at MNKD technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on MNKD Technicals page.